ESR1 and breast cancer: The latest research proves that about 70% of all cases are estrogen receptor-positive (ER+), whereas triple-negative BC (TNBC), lacking estrogen receptors, progesterone receptors (PR), and the human epidermal growth factor receptor 2 (Her2), constitute 10–20% of BC cases [3,4].